Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03413917 · ClinicalTrials.gov registry record
Exploration and Determination of Genomic Markers Predictive of Uterine Atony
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 21
- Enrollment target
NCT03413917: Completed study, sponsored by Baylor Research Institute.
NCT03413917 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03413917 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine whether there are markers in the tissue of atonic uteri, and in the patients' plasma that would help identify patients likely to suffer postpartum hemorrhage due to uterine atony. We also will attempt to identify the cause(s) of uterine atony that might suggest mechanisms to prevent and manage it.
Primary Outcome
To extract RNA from serum and uterine tissue samples and use Next Generation miRNA Sequencing followed by quantification of serum miRNA and miRNA isoform expression using TaqMan miRNA assays and NanoString.
Interventions
- OTHER Analysis of genomic markers in uterine atony
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-02-02 |
| Est. Completion | 2020-07-01 |
What the finished NCT03413917 record still lists
NCT03413917 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Analysis of genomic markers in uterine atony is the first listed.
NCT03413917 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03413917 about?
NCT03413917 is a clinical study titled "Exploration and Determination of Genomic Markers Predictive of Uterine Atony". The primary objective of this study is to determine whether there are markers in the tissue of atonic uteri, and in the patients' plasma that would help identify patients likely to suffer postpartum hemorrhage due to uterine atony. We also will attempt to identify the cause(s) of uterine atony that ...
What is the current status of trial NCT03413917?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2018-02-02. Estimated completion is 2020-07-01.
What interventions are being tested in trial NCT03413917?
The interventions under investigation include: Analysis of genomic markers in uterine atony (OTHER).
Who is sponsoring clinical trial NCT03413917?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI